Managing Bone Loss Associated with Androgen Deprivation Therapy

To start this activity, click Begin at the bottom of this page Managing Bone Loss Associated with Androgen Deprivation Therapy

Release Date: June 2013

Expiration Date: June 2014

Estimated time to complete the educational activity: 1 hour

This activity is jointly sponsored by Medical Education Resources and Haymarket Medical Education.

Statement of Need: Although ADT has been shown to improve outcomes in men with advanced prostate cancer (PCa), it does not come without significant adverse effects. ADT is well known to accelerate bone loss and to increase risk of fractures. Since urologists are often the first practitioners to treat their patients with ADT and to diagnose bone metastases, they should be aware of appropriate bone protective agents that should be prescribed.

Target Audience: This activity has been designed to meet the needs of urologists, and allied healthcare clinicians who treat prostate cancer patients with ADT.

Educational Objectives: After completing the activity, the participant should be better able to:

  • Assess fracture risk for men undergoing androgen deprivation therapy
  • Discuss treatment options for prostate cancer patients with ADT-induced bone loss and bone metastases

Accreditation Statement:This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER) and Haymarket Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: Medical Education Resources designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest: Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality CME activities that promote improvements or quality in health care and not a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:

Name of Faculty Reported Financial Relationship
J. Bryant Byrd, MD No financial relationships to disclose
William J. Aronson, MD Grants/Research Support: NIH/NCI P50CA92131 Consultant: Amgen, Dendreon, Janssen, Medivation Speakers' Bureau: Amgen, Janssen, Medivation

The content managers, Jody A. Charnow and Marina Galanakis, of Haymarket Medical Education, and Julie Johnson, PharmD, of Medical Education Resources, have disclosed that they have no relevant financial relationships or conflicts of interest.

Method of Participation: There are no fees for participating in and receiving CME credit for this activity. During the period December 2012 through December 2013, participants must: 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest and submit it online. Physicians may register at www.myCME.com/renalandurologynews, and 4) complete the evaluation form online.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.

Page 1 of 6
Loading links....
You must be a registered member of Renal and Urology News to post a comment.